Innate Pharma announced data for two Phase I studies for lirilumab and nivolumab
Monday, October 10, 2016
Innate Pharma SA Announced on Sunday safety data for two Phase I studies conducted by Bristol-Myers Squibb.
Combination of lirilumab and nivolumab in Phase I study of advanced solid tumors showed no added toxicity over nivolumab monotherapy. Data supports ongoing Phase I cohort expansion of lirilumab in combination with nivolumab.
Efficacy data will be presented at Society for Immunotherapy of Cancer 2016 conference.
Source : reuters.com
